Closely held Wandercraft has announced the acquisition of Ekso Bionics from a subsidiary of ChronoScale Holdings Corporation (NASDAQ: CHRN), uniting two leaders in robotic mobility to form the world’s leading medical exoskeleton company.
According to Wandercraft, the acquisition combines its expertise in advanced robotics and physical AI and its leadership in EMEA with Ekso Bionics’ strong U.S. presence, extensive clinical experience, and commercial reach. Both companies have been trailblazers in medical exoskeletons, driving technological innovation, R&D, and clinical research. The combination creates a global powerhouse in robotic mobility, with a broader portfolio of medical exoskeletons spanning the continuum of care, from rehabilitation to everyday personal mobility.
In a statement, Matthieu Masselin, CEO and co-founder of Wandercraft, commented, “We share a vision for how robotics can empower people whose mobility has been unfairly limited by injury or disease. Both companies have pioneered advanced technologies to help people stand, walk, and participate more fully in everyday life. By bringing together our products, teams, and clinical relationships on both sides of the Atlantic, we have an exceptional opportunity to expand access to robotic mobility worldwide, reach more patients and rehabilitation professionals, and help more people experience the independence and connection that upright mobility can offer.”
Scott Davis, CEO of Ekso Bionics, remarked, “Ekso has spent two decades pioneering robotic technologies, advancing engineering and R&D, and building a robust body of clinical research and evidence that has earned the trust of clinicians and the people who rely on our products. Joining Wandercraft represents an exciting next chapter, uniting two organizations with a shared commitment to mobility, rehabilitation, and innovation. Together, we can build on that trailblazing work and expand our ability to develop and deploy technologies that make a meaningful difference for more people.”
